Interested in joining the Committee for Advanced Therapies (CAT) to represent patients' associations or clinicians?
Call for expressions of interest open until 18 July 2018
The European Commission has published a call for expressions of interest for representatives of patients' organisations and clinicians to join the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) as members and alternates.
This call is intended to select candidates to replace the Committee's current civil society representatives. The Commission will appoint two members representing patients' associations and two members representing clinicians, as well as alternates for each of them. They will be appointed for a three-year mandate starting on 1 July 2019.
Expressions of interest should be submitted to the European Commission no later than 18 July 2018, either by e-mail to email@example.com or by post. Interested parties should complete both application forms and the form on declarations of interests, which can be downloaded from the European Commission's website. Candidates will be informed of the outcome of the selection process.
The civil society representatives are expected to bring the perspectives of patients and clinicians to the work of the CAT. Their role is to provide input based on their real-life experience and to contribute to the assessment of medicines and regulatory decision-making.
The appointed representatives are expected to attend the two-day monthly meetings of the CAT, contribute to scientific discussions, examine documents and make comments during the meetings.
The CAT's main responsibility is to assess the quality, safety and efficacy of advanced therapy medicinal products (ATMPs) and following scientific developments in the field. Established as a multidisciplinary committee, it brings together some of Europe's best experts in advanced therapy medicines derived from gene therapy, cell therapy or tissue engineering.